Brief: 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

4D Molecular Therapeutics

06/06/2024 12:48

June 6 (Reuters) - 4D Molecular Therapeutics Inc
 FDMT.O :
    * 4DMT PRESENTS POSITIVE INTERIM DATA FROM PHASE 1/2 AEROW
CLINICAL TRIAL OF AEROSOLIZED 4D-710 FOR
MODULATOR-INELIGIBLE/-INTOLERANT CYSTIC FIBROSIS AT 47TH
EUROPEAN CYSTIC FIBROSIS CONFERENCE
    * 4D MOLECULAR THERAPEUTICS INC: 1E15 VG DOSE CLEARED FOR
EVALUATION IN PHASE 2 DOSE EXPANSION STAGE
    * 4D MOLECULAR THERAPEUTICS INC: ENROLLMENT EXPECTED TO
BEGIN IN
H2 2024 AND NEXT INTERIM DATA UPDATE EXPECTED IN MID-2025
    * 4D MOLECULAR THERAPEUTICS- CLINICALLY MEANINGFUL
IMPROVEMENTS IN
PPFEV AT 12 MONTHS OBSERVED IN 2 PARTICIPANTS WITH BASELINE LUNG
FUNCTION IMPAIRMENT

Source text for Eikon:  ID:nGNX6LhW2h 
Further company coverage:  FDMT.O 

 ((Reuters.Briefs@thomsonreuters.com;))